Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report)’s stock price was down 0.4% during trading on Wednesday . The company traded as low as $4.75 and last traded at $4.75. Approximately 8,924 shares changed hands during trading, a decline of 57% from the average daily volume of 20,670 shares. The stock had previously closed at $4.77.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Friday, April 26th.
Get Our Latest Stock Analysis on NBTX
Nanobiotix Price Performance
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
- Five stocks we like better than Nanobiotix
- The Role Economic Reports Play in a Successful Investment Strategy
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Earnings Per Share Calculator: How to Calculate EPS
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How Can Investors Benefit From After-Hours Trading
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
